US stock futures flounder amid tech weakness, Fed caution
IRVINE, Calif. - ReShape Lifesciences (NASDAQ:RSLS), known for its weight loss and metabolic health solutions, has entered into an exclusive distribution agreement with Motion Informatics to bring advanced neuromuscular rehabilitation devices to the U.S. market. The agreement, announced today, highlights the Stimel-03, a device that received attention at the American Occupational Therapy Association 2025 Annual Conference and Expo in Philadelphia earlier this month. With a market capitalization of $1.13 million and annual revenue of $8.01 million, ReShape maintains a strong gross margin of 63.17% despite challenging market conditions. According to InvestingPro analysis, the company appears undervalued based on its Fair Value metrics.
The Stimel-03, which is FDA cleared and commercially available, integrates Functional Electrical Stimulation (FES), Neuromuscular Electrical Stimulation (NMES), and real-time electromyographic (EMG) biofeedback into one platform. It is designed to aid patients in recovery from events such as strokes, injuries, or surgeries. Paul F. Hickey, President and CEO of ReShape Lifesciences, emphasized the alignment of Motion Informatics' devices with their mission to improve patient outcomes and drive clinical and commercial impact. For detailed financial analysis and 12+ additional ProTips about RSLS, investors can access the comprehensive Pro Research Report available on InvestingPro.
Motion Informatics is at the forefront of neuromuscular rehabilitation, integrating AI, augmented reality (AR), and digital health into a therapeutic platform. Their Spatial StimelMD (SSMD) system is the first closed-loop neuromotor intelligence system that combines personalized neuromodulation, real-time EMG biofeedback, and augmented reality. Gary Sagiv, CEO of Motion Informatics, expressed confidence in ReShape's commercial reach to successfully distribute their products across the U.S.
ReShape Lifesciences offers a portfolio of products and services for obesity and metabolic disease management, including the FDA-approved Lap-Band® System and the investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system. The company's Obalon® balloon technology is a non-surgical, swallowable intra-gastric balloon aimed at long-lasting weight loss.
This partnership is poised to enhance the availability of cutting-edge neurorehabilitation solutions in the U.S., potentially impacting the way clinicians approach the care and recovery of patients with neuromuscular conditions. While the company's stock has faced significant challenges, with a current ratio of 0.92 and trading at historically low levels, InvestingPro data suggests potential opportunities for value investors. The information disclosed in this article is based on a press release statement and financial data from InvestingPro's extensive database of over 1,400 detailed company reports.
In other recent news, ReShape Lifesciences Inc. has reported several significant developments. The company announced shareholder approval for key proposals during a special meeting, including a reverse stock split, warrant exercisability, and an Equity Line of Credit agreement. These approvals are expected to provide ReShape with greater flexibility in managing its capital structure and funding strategy. Additionally, ReShape has secured an international patent for its Diabetes Neuromodulation technology, which aims to improve glycemic control for Type 2 diabetes patients. This patent, granted by the State of Israel Patent Office, extends protection until December 4, 2039.
In parallel, ReShape has amended the terms of its senior secured convertible note with Ascent Partners Fund LLC, extending the note's maturity date and adjusting prepayment conditions. This amendment is strategically aligned with the company's anticipated merger with Vyome Therapeutics Inc. The merger, an all-stock transaction, is progressing as planned, with ReShape set to become Vyome Holdings, Inc. and trade under the new ticker symbol "HIND" post-closing. The merger aims to advance Vyome's immuno-inflammatory assets and explore opportunities between the Indian and U.S. markets.
Furthermore, ReShape has entered into an asset purchase agreement with Biorad Medisys, which will acquire most of ReShape's assets, excluding cash. These recent developments highlight ReShape's strategic efforts to enhance its financial position and expand its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.